A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants
Journal article published in 2021 by
Denise Haslwanter 
,
M. Eugenia Dieterle ,
Anna Z. Wec,
Cecilia M. O’Brien,
Mrunal Sakharkar,
Catalina Florez,
Karen Tong,
C. Garrett Rappazzo,
Gorka Lasso,
Olivia Vergnolle,
Ariel S. Wirchnianski,
Robert H. Bortz,
Ethan Laudermilch,
J. Maximilian Fels,
Amanda Mengotto
and other authors.
,
M. Eugenia Dieterle ,
Anna Z. Wec,
Cecilia M. O’Brien,
Mrunal Sakharkar,
Catalina Florez,
Karen Tong,
C. Garrett Rappazzo,
Gorka Lasso,
Olivia Vergnolle,
Ariel S. Wirchnianski,
Robert H. Bortz,
Ethan Laudermilch,
J. Maximilian Fels,
Amanda Mengotto
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Data provided by 
Abstract
The U.S. FDA has issued emergency use authorizations (EUAs) for multiple investigational monoclonal antibody (MAb) therapies for the treatment of mild to moderate COVID-19.